口腔鳞状细胞癌及PD-1/PD-L1相关免疫治疗方法的分子基础、潜在生物标志物及未来前景
Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods.
作者信息
Cheng Yuxi, Song Zhengzheng, Chen Juan, Tang Zhangui, Wang Baisheng
机构信息
Xiangya Stomatological Hospital, Central South University, Changsha, 410008, China.
Xiangya School of Stomatology, Central South University, Changsha, 410008, China.
出版信息
Heliyon. 2024 Feb 10;10(4):e25895. doi: 10.1016/j.heliyon.2024.e25895. eCollection 2024 Feb 29.
Oral squamous cell carcinoma (OSCC) affects a large number of individuals worldwide. Despite advancements in surgery, radiation, and chemotherapy, satisfactory outcomes have not been achieved. In recent years, the success of drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has led to breakthroughs in cancer treatment, but systematic summaries on their effectiveness against OSCC are lacking. This article reviews the latest research on the PD-1/PD-L1 pathway and the potential of combination therapy based on this pathway in OSCC. Further, it explores the mechanisms involved in the interaction of this pathway with exosomes and protein-protein interactions, and concludes with potential future OSCC therapeutic strategies.
口腔鳞状细胞癌（OSCC）在全球影响着大量人群。尽管手术、放疗和化疗取得了进展，但仍未取得令人满意的治疗效果。近年来，靶向程序性细胞死亡蛋白1（PD-1）和程序性细胞死亡配体1（PD-L1）的药物取得成功，带来了癌症治疗的突破，但缺乏关于其对OSCC有效性的系统总结。本文综述了关于PD-1/PD-L1通路的最新研究以及基于该通路的联合治疗在OSCC中的潜力。此外，探讨了该通路与外泌体相互作用以及蛋白质-蛋白质相互作用所涉及的机制，并以OSCC未来潜在的治疗策略作为结论。
Zotero 插件